Phase 3
Completed N=87
Brain Imaging and Treatment Studies of the Night Eating Syndrome
Night Eating Syndrome
Source: ClinicalTrials.gov NCT01401595 ↗
Enrolled (actual)
87
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Change in Symptoms of NES — 46.1; 11.8; 17.4; NA percentage of calories after dinner
◆ Published Evidence
Established
32citations · ~2 / year
An open-label efficacy trial of escitalopram for night eating syndrome.
Summary
The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.
Linked Publications
-
An open-label efficacy trial of escitalopram for night eating syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Symptoms of NES |
46.1; 11.8; 17.4; NA | — |
| SECONDARY Nocturnal Ingestions |
5.8; 0.0; 1.2; NA | — |
| SECONDARY Night Eating Symptoms |
30.2; NA; 15.2; NA | — |
Eligibility Criteria
Inclusion Criteria
- men and women suffering from NES
- ages 18 to 70 years
- BMI greater than 18.5 kg/m2
Exclusion Criteria
- Children or adolescents <18 years
- persons older than 70
- patients with diabetes mellitus
- thyroid disease and other endocrine and metabolic disorders
- use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics
- current anorexia nervosa or bulimia nervosa
- participation in an organized weight reduction program
- use of antiobesity medication
- an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)
- Bipolar Disorder
- suicidal risk
- current or past psychosis
- substance use or abuse disorder within the past 6 months
Data sourced from ClinicalTrials.gov (NCT01401595) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.